Literature DB >> 8636750

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma.

D Meitar1, S E Crawford, A W Rademaker, S L Cohn.   

Abstract

PURPOSE: To determine if the clinical outcome of children with neuroblastoma (NB) is correlated with the degree of tumor neovascularization and to assess the relationship of stage, N-myc copy number, and histology to angiogenesis.
MATERIALS AND METHODS: The vascularity of primary untreated NB from 50 patients diagnosed at a single institution between 1984 and 1994 was evaluated. An image processor was used to analyze the tumor tissue area for each histologic slide of tumor, and a vascular index (VI) was calculated, where VI = total number of vessels/mm2 of tissue area. Tumors were classified histologically according to the criteria of Shimada et al (J Natl Cancer Inst 73:405-416, 1984), and N-myc copy number was determined by Southern blot analysis.
RESULTS: We found that higher VI (> 4.0) in NB strongly correlated with widely disseminated disease (P = .006) and poor survival (P < .0001). VI more than 4.0 was also statistically associated with N-myc amplification (P = .02) and unfavorable histology (P = .02). Univariate analysis demonstrated that disease stage, tumor histology, and N-myc copy number were also predictive of outcome. Cox regression analysis showed that VI provided independent prognostic information.
CONCLUSION: Our studies indicate that angiogenesis may play an important role in determining the biologic behavior of NB. Antiangiogenic therapy may prove to be effective in the treatment of children with highly vascular, widely disseminated NB.

Entities:  

Mesh:

Year:  1996        PMID: 8636750     DOI: 10.1200/JCO.1996.14.2.405

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  77 in total

1.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers.

Authors:  Jiyun Shi; Lijun Wang; Young-Seung Kim; Shizhen Zhai; Zhaofei Liu; Xiaoyuan Chen; Shuang Liu
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Authors:  Louis Chesler; Chris Schlieve; David D Goldenberg; Anna Kenney; Grace Kim; Alex McMillan; Katherine K Matthay; David Rowitch; William A Weiss
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts.

Authors:  Shuqing Liu; Yufeng Tian; Alexandre Chlenski; Qiwei Yang; Peter Zage; Helen R Salwen; Susan E Crawford; Susan L Cohn
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer.

Authors:  Shuang Liu; Young-Seung Kim; Wen-Yuan Hsieh; Subramanya Gupta Sreerama
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

6.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

7.  Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Authors:  C Lu; L Everhart; J Tilan; L Kuo; C-C J Sun; R B Munivenkatappa; A-C Jönsson-Rylander; J Sun; A Kuan-Celarier; L Li; K Abe; Z Zukowska; J A Toretsky; J Kitlinska
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

8.  Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.

Authors:  W T Arscott; A E LaBauve; V May; U V Wesley
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

9.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

10.  Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis.

Authors:  Gordana Jakovljević; Srana Culić; Jasminka Stepan; Aleksandra Bonevski; Sven Seiwerth
Journal:  J Exp Clin Cancer Res       Date:  2009-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.